

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Ferroptosis Inhibitor D1

Item No. 41822

Formal Name: N1-cyclohexyl-5-(2-methyl-2H-

tetrazol-5-yl)benzene-1,2-diamine

MF: $C_{14}H_{20}N_6$ FW: 272.4 **Purity:** ≥98%

Supplied as: A crystalline solid

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

 H_2N

Laboratory Procedures

Ferroptosis inhibitor D1 is supplied as a crystalline solid. A stock solution may be made by dissolving the ferroptosis inhibitor D1 in the solvent of choice, which should be purged with an inert gas. Ferroptosis inhibitor D1 is soluble (≥10 mg/ml) in DMSO.

Description

Ferroptosis inhibitor D1 is a free radical scavenger and an inhibitor of ferroptosis. 1 It scavenges 41.27% of DPPH (Item No. 14805) radicals in a cell-free assay when used at a concentration of 0.4 μM. Ferroptosis inhibitor D1 (0.5 µM) inhibits lipid peroxidation induced by the ferroptosis inducer erastin (Item No. 17754) in HT-1080 cells and inhibits erastin-induced ferroptosis in the same cells (IC_{50} = 22 nM). In vivo, ferroptosis inhibitor D1 (5 mg/kg) reduces infarct volume and improves neurological deficits in a mouse model of ischemic brain injury induced by transient middle cerebral artery occlusion (MCAO).

Reference

1. Lu, Y., Shen, Z., Xu, Y., et al. Discovery of new phenyltetrazolium derivatives as ferroptosis inhibitors for treating ischemic stroke: An example development from free radical scavengers. J. Med. Chem. 67(14), 11712-11731 (2024).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 08/30/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM